Abstract:After advanced age, female sex is the major risk factor for late-onset Alzheimer’s disease (AD), the most common cause of dementia affecting over 24 million people worldwide. The prevalence of AD is higher in women than in men, with postmenopausal women accounting for over 60% of all those affected. While most research has focused on gender-combined risk, emerging data indicate sex and gender differences in AD pathophysiology, onset, and progression, which may help account for the higher prevalence in women. Notably, AD-related brain changes develop during a 10–20 year prodromal phase originating in midlife, thus proximate with the hormonal transitions of endocrine aging characteristic of the menopause transition in women. Preclinical evidence for neuroprotective effects of gonadal sex steroid hormones, especially 17β-estradiol, strongly argue for associations between female fertility, reproductive history, and AD risk. The level of gonadal hormones to which the female brain is exposed changes considerably across the lifespan, with relevance to AD risk. However, the neurobiological consequences of hormonal fluctuations, as well as that of hormone therapies, are yet to be fully understood. Epidemiological studies have yielded contrasting results of protective, deleterious and null effects of estrogen exposure on dementia risk. In contrast, brain imaging studies provide encouraging evidence for positive associations between greater cumulative lifetime estrogen exposure and lower AD risk in women, whereas estrogen deprivation is associated with negative consequences on brain structure, function, and biochemistry. Herein, we review the existing literature and evaluate the strength of observed associations between female-specific reproductive health factors and AD risk in women, with a focus on the role of endogenous and exogenous estrogen exposures as a key underlying mechanism. Chief among these variables are reproductive lifespan, menopause status, type of menopause (spontaneous vs. induced), number of pregnancies, and exposure to hormonal therapy, including hormonal contraceptives, hormonal therapy for menopause, and anti-estrogen treatment. As aging is the greatest risk factor for AD followed by female sex, understanding sex-specific biological pathways through which reproductive history modulates brain aging is crucial to inform preventative and therapeutic strategies for AD.

Estrogen, Cognitive Performance, and Functional Imaging Studies: What Are We Missing About Neuroprotection?

Estrogens as neuroprotectants: Estrogenic actions in the context of cognitive aging and brain injury

Research progress of relationship between estrogen and cognition in women

In vivo brain estrogen receptor density by neuroendocrine aging and relationships with cognition and symptomatology

Endogenous Estrogens and Brain Activation During Verbal Memory Encoding and Recognition in the Postmenopause

Estradiol and cognitive function: Past, present and future

Estrogen receptor α: a critical role in successful female cognitive aging

Frontiers proposal. National Institute on Aging “bench to bedside: estrogen as a case study”

Systematic review and meta-analysis of the effects of menopause hormone therapy on cognition

Altered Spontaneous Brain Activity in Women During Menopause Transition and Its Association With Cognitive Function and Serum Estradiol Level

Menopause and Brain Health: Hormonal Changes Are Only Part of the Story

Estradiol associations with brain functional connectivity in postmenopausal women

Influence of the Onset of Menopause on the Risk of Developing Alzheimer's Disease

Endogenous and Exogenous Estrogen Exposures: How Women’s Reproductive Health Can Drive Brain Aging and Inform Alzheimer’s Prevention

The benefits of estradiol on cognitive aging in rats are independent from its effects on cardiometabolic health

Estrogen: a neuroprotective or proinflammatory hormone? Emerging evidence from reproductive aging models

Neuroprotective effect of hormone replacement therapy: a review of the literature

Transitions in metabolic and immune systems from pre-menopause to post-menopause: implications for age-associated neurodegenerative diseases

Menopause impacts human brain structure, connectivity, energy metabolism, and amyloid-beta deposition

From Menopause to Neurodegeneration—Molecular Basis and Potential Therapy

Sex hormones, vascular factors and cognition